Kenneth Tandjung

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients

Clemens von Birgelen, Mounir W.Z. Basalus, Kenneth Tandjung et al. · Journal of the American College of Cardiology · 2012 · 248 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis

Eliano Pio Navarese, Kenneth Tandjung, Bimmer E. Claessen et al. · BMJ · 2013 · 236 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

Clemens von Birgelen, Hanim Sen, Ming Kai Lam et al. · The Lancet · 2013 · 198 citations

Medicine, Cardiology, Internal Medicine +15

Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents

Kenneth Tandjung, Hanim Sen, Ming Kai Lam et al. · Journal of the American College of Cardiology · 2013 · 71 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry

Frits H.A.F. de Man, Kenneth Tandjung, Marc Hartmann et al. · EuroIntervention · 2012 · 70 citations · Full text

Medicine, Cardiology, Surgery +12